DENVER — MCO-010, an optogenetic therapy, demonstrated vision improvements for patients with retinitis pigmentosa at 3 years, according to a presenter at the Association for Research in Vision and Ophthalmology meeting.
Optogenetic treatment for retinal disease focuses on restoring light sensitivity to retinal cells through the delivery of synthetic protein, Vinit B. Mahajan, MD, PhD, a retina specialist at Stanford University, told Healio. MCO-010 (Nanoscope Therapeutics), he said, is gene-agnostic.
{{VIDEO}}
“We’re not picking a specific [form of] retinitis pigmentosa (RP),” Mahajan told
— Curated from external eye-care sources for opthametry.com readers.
📰 Original Source: Healio Ophthalmology
Discover more from An Eye Care Blog
Subscribe to get the latest posts sent to your email.
